Enhanced 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol Compounds and Systems for CDK-Mediated Diseases
Legal Citation
Summary of the Inventive Concept
The inventive concept presents a suite of direct improvements and enhancements to the original CDK inhibitor compounds, focusing on improved solubility, bioavailability, and synthesis efficiency, as well as novel pharmaceutical compositions and crystalline forms, to provide more effective and efficient treatments for CDK-mediated diseases.
Background and Problem Solved
The original patent disclosed CDK inhibitor compounds with limited solubility and bioavailability, resulting in reduced efficacy and increased side effects. The inventive concept addresses these limitations by introducing novel formulations, synthesis methods, and crystalline forms that enhance the compounds' properties, providing better treatment options for patients.
Detailed Description of the Inventive Concept
The inventive concept comprises five key aspects: (1) a system for treating CDK-mediated diseases with improved solubility and bioavailability compounds; (2) a method for synthesizing these compounds using novel catalysts to enhance reaction yields and reduce impurities; (3) pharmaceutical compositions with sustained release properties; (4) a process for preparing substantially purified compounds through crystallization, recrystallization, and chromatography; and (5) novel crystalline forms with improved stability and shelf life. These enhancements collectively provide more effective and efficient treatments for CDK-mediated diseases.
Novelty and Inventive Step
The inventive concept's novelty lies in the combination of improved solubility, bioavailability, and synthesis efficiency, as well as the introduction of novel pharmaceutical compositions and crystalline forms. The inventive step is the recognition of the need to address the original patent's limitations and the development of these direct improvements and enhancements.
Alternative Embodiments and Variations
Alternative embodiments may include the use of different solvents or excipients in the pharmaceutical compositions, variations in the synthesis methods, or alternative crystalline forms. These variations can provide additional flexibility in the development and commercialization of the inventive concept.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the treatment of CDK-mediated diseases such as cancer. The improved compounds and systems can provide more effective and efficient treatments, resulting in improved patient outcomes and reduced healthcare costs.
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Medicinal Chemistry and Pharmaceutical Formulation, specifically focused on CDK inhibitor compounds and their pharmaceutical development, requiring expertise in organic synthesis, drug design, and pharmaceutical formulation techniques
Person of Ordinary Skill (PHOSITA) Profile
A skilled practitioner with a PhD in medicinal chemistry or pharmaceutical sciences, with 5-10 years of experience in drug development, familiar with synthetic organic chemistry techniques, pharmaceutical formulation strategies, and structure-activity relationship analysis
Obviousness Rationale
The Published Technical Disclosure presents incremental improvements to the source patent's CDK inhibitor compounds that would be considered routine optimization by a person having ordinary skill in the art. These variations represent predictable extensions of the original compound's design, addressing common pharmaceutical development challenges such as solubility, bioavailability, and synthesis efficiency through well-established pharmaceutical engineering techniques.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,552 |
|---|---|
| Title | 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors |
| Assignee(s) | CARRICK THERAPEUTICS LIMITED |